Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412024 | 0.76 | — | — | |
| SCHEMBL5377204 | 0.73 | KMT2A (0.49) | LMNAKMT2AATM | |
| SCHEMBL4413215 | 0.72 | RECQL (0.42) | LMNANPSR1NPC1RAB9AKMT2A | |
| SCHEMBL4413264 | 0.71 | — | — | |
| SCHEMBL5754487 | 0.71 | — | — | |
| SCHEMBL10189371 | 0.71 | MAPT (0.42) | CNR2LMNATP53MAPTNPSR1 | |
| SCHEMBL4412009 | 0.69 | PKM (0.34) | CNR2PKMATMHSD17B10 | |
| SCHEMBL25958865 | 0.69 | MAOB (0.38) | PKMATMHSD17B10 | |
| SCHEMBL1324895 | 0.69 | PKM (0.34) | KMT2APKMATMHSD17B10 | |
| SCHEMBL12603040 | 0.69 | PKM (0.34) | KMT2APKMATMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097594-B2 | Macrolides and ketolides having antimicrobial activity | WOCKHARDT LTD. (IN) | 2012-01-17 | — | — | US | disclosed |
| US-20100152185-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | CHU LIN | 2010-06-17 | — | — | US | disclosed |
| US-7629467-B2 | 5-lipoxygenase activating protein inhibitors; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | SINDKHEDKAR MILIND DATTATRAYA | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | CYP51A1, CASP12, LSS | CNR2 4517/4885LMNA 2135/4885TP53 4723/4885 |
| US-20100152185-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | ALOX5, LTC4S, ALOX15 | CNR2 327/4885LMNA 1308/4885TP53 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.